The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Bicara Therapeutics Inc shares valued at $32,994,000 were purchased by RA CAPITAL MANAGEMENT, L.P. on Sep 16 ’24. At $18.00 per share, RA CAPITAL MANAGEMENT, L.P. acquired 1,833,000 shares. The insider’s holdings grew to 4,303,418 shares worth approximately $67.78 million following the completion of this transaction.
Also, Flynn James E purchased 70,000 shares, netting a total of over 1,260,000 in proceeds. Following the buying of shares at $18.00 each, the insider now holds 897,587 shares.
As published in their initiating research note from Wedbush on February 06, 2025, Bicara Therapeutics Inc [BCAX] has been an Outperform and the price target has been revised to $31. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early December. As of November 05, 2024, Rodman & Renshaw has initiated its “Buy” rating for BCAX. Earlier on October 08, 2024, TD Cowen initiated its rating. Their recommendation was “a Buy” for BCAX stock.
Analyzing BCAX Stock Performance
During the last five days, there has been a surge of approximately 27.43%. Over the course of the year, Bicara Therapeutics Inc shares have dropped approximately -9.59%.
Support And Resistance Levels for Bicara Therapeutics Inc (BCAX)
According to the 24-hour chart, there is a support level at 14.72, which, if violated, would cause prices to drop to 13.70. In the upper region, resistance lies at 16.30. The next price resistance is at 16.86. RSI (Relative Strength Index) is 66.30 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.41, which suggests the price will increase in the coming days. Percent R is at 1.97%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
